^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

3249 / 22 - Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors

Published date:
03/15/2023
Excerpt:
Pre-treatment, patients with durable clinical benefit (DCB) had higher IL23, lower CXCL6, and lower IL10 levels….Baseline measurement of cytokines IL23, CXCL6, and IL10 can predict metastatic melanoma patients’ response to ipi/nivo combination treatment.